3-氨基-4-[(1-苄基-2-甲氧基-2-氧代乙基)氨基]-4-氧代丁酸 | 25548-16-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 3-氨基-4-[(1-苄基-2-甲氧基-2-氧代乙基)氨基]-4-氧代丁酸
• 英文名称: aspartame
• 英文别名: 3-Azaniumyl-4-[(1-methoxy-1-oxo-3-phenylpropan-2-yl)amino]-4-oxobutanoate
• CAS: 25548-16-7
• 化学式: C₁₄H₁₈N₂O₅
• mdl: MFCD00002724
• 分子量: 294.307
• InChiKey: IAOZJIPTCAWIRG-UHFFFAOYSA-N

物化性质

• 熔点：
  248 °C
• 沸点：
  535.8±50.0 °C(Predicted)
• 密度：
  1.280±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -2.7
• 重原子数：
  21
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.357
• 拓扑面积：
  119
• 氢给体数：
  3
• 氢受体数：
  6

ADMET

毒理性

• 在妊娠和哺乳期间的影响

哺乳期使用总结：阿斯巴甜在母亲摄入后不会在母乳中被检测到，因为它在母亲体内迅速分解。即使摄入极大的阿斯巴甜（相当于17罐汽水或100包等量甜味剂）也只能略微提高母乳中的苯丙氨酸含量。在单次大量摄入阿斯巴甜后12小时内，乳汁中的苯丙氨酸浓度会恢复到基线水平。尽管建议哺乳妇女避免使用阿斯巴甜，特别是如果婴儿患有苯丙酮尿症，但通常摄入的阿斯巴甜含量在含阿斯巴甜的食品和饮料中并不会给患有苯丙酮尿症的哺乳婴儿带来额外风险。摄入含有低热量甜味剂的减肥饮料可能会增加哺乳婴儿呕吐的风险。 对哺乳婴儿的影响：一项横断面调查评估了美国母亲在婴儿11到15周大时哺乳的饮食历史。调查用来估计妇女摄入的无糖汽水和果汁饮料的量。根据低热量甜味剂暴露，婴儿的体重或z得分没有统计学上的显著差异。然而，每周只接触一次或更少低热量甜味剂的婴儿比那些未接触的婴儿有统计学上显著更高的呕吐风险。更高频率的暴露与呕吐无关。无法评估特定甜味剂的影响。 对泌乳和母乳的影响：截至修订日期，未找到相关的已发布信息。

◉ Summary of Use during Lactation:Aspartame is not detectable in breastmilk after maternal ingestion because it is rapidly broken down in the mother's body. An extremely large intake of aspartame (equivalent to 17 cans of soda or 100 packets of Equal Sweetener) can slightly increase the amount of phenylalanine in breastmilk. Phenylalanine concentrations in milk return to baseline by 12 hours after a large single dose of aspartame. Although it is prudent to avoid the use of aspartame in women who are nursing an infant with phenylketonuria, amounts that are typically ingested in aspartame-sweetened foods and beverages do not result in any additional risk to breastfed infants with phenylketonuria. Ingestion of diet drinks containing low-calorie sweeteners might increase the risk of vomiting in breastfed infants. ◉ Effects in Breastfed Infants:A cross-sectional survey assessed the dietary history of US mothers nursing infants between 11 and 15 weeks of age. The survey was used to estimate the amount of diet soda and fruit drinks consumed by the women. There were no statistically significant differences in infants’ weight or z-scores based on low calorie sweetener exposure. However, infants exposed to low calorie sweetener in milk once or less per week had a statistically significantly higher risk of vomiting than those who were not exposed. Greater exposure was not associated with vomiting. It was not possible to assess the effects of specific sweeteners. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2924293000
• 储存条件：
  室温

SDS

Name:	3-Amino-4-[(1-benzyl-2-methoxy-2-oxoethyl)amino]-4-oxobutanoic acid Material Safety Data Sheet
Synonym:	L-Aspartyl-1-phenylalanine, methylester; Aspartame
CAS:	25548-16-7

Section 1 - Chemical Product MSDS Name:3-Amino-4-[(1-benzyl-2-methoxy-2-oxoethyl)amino]-4-oxobutanoic acid Material Safety Data Sheet
Synonym:L-Aspartyl-1-phenylalanine, methylester; Aspartame

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
25548-16-7	3-Amino-4-[(1-benzyl-2-methoxy-2-oxoet	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Never give anything by mouth to an unconscious person. Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with eyes, skin, and clothing.
Keep container tightly closed. Avoid ingestion and inhalation. Use with adequate ventilation. Wash clothing before reuse.
Storage:
Keep refrigerated. (Store below 4C/39F.) Store in a tightly closed container. Store in a dry area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 25548-16-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: white - slight pink
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 248 - 250 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C14H18N2O5
Molecular Weight: 294.31

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Acids, acid chlorides, bases, reducing agents, strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 25548-16-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Amino-4-[(1-benzyl-2-methoxy-2-oxoethyl)amino]-4-oxobutanoic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 25548-16-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 25548-16-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 25548-16-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  hydrotris(3,5-methylphenylpyrazolyl)boratozinc(II) hydroxide 、 3-氨基-4-[(1-苄基-2-甲氧基-2-氧代乙基)氨基]-4-氧代丁酸 以 乙醇 、 二氯甲烷 为溶剂， 以37%的产率得到
  参考文献：
  名称：

  Coordination modes of aminoacids to zinc

  摘要：

  Two new binary zinc-aminoacid complexes were crystallized: Zn(Ile)(2)(H2O)(2) is octahedral with two O,N-chelating aminoacid ligands; Zn(Phe)(2) is a one-dimensional coordination polymer with eta(2)-carboxylate bridges. The pyrazolylborate zinc complex Tp(Ph,Me)Zn-OH reacted with simple aminoacids to form the complexes Tp(Ph,Me)Zn-AA (AA = Gly, Val, Leu, Met, Phe, Trp) in which AA is a O,N-chelate ligand. In a similar fashion aminoacid-nitroanilides were deprotonated at the N atom yielding the Tp(Ph),Zn-Me complexes with the N,N-chelating ligands Gly-Nit, Ala-Nit and Leu-Nit. When terminal amino functions were missing, pure carboxylate coordination resulted, as in Tp(Ph,Me)Zn-GlyPheBoc and Tp(Ph,Me)Zn-AspPheOMe. Exclusive side-chain coordination was enforced in Bz-Tyr-OEt resulting in the Tp(Ph,Me)Zn complex with the phenolate-bound aminoacid. Combinations of the binding types (O,N-chelate+carboxylate, O,N-chelate+phenolate, O,N-chelate+thiolate) were realized in the binuclear complexes Tp(Ph,Me)Zn-AA-ZnTp(Ph,Me) for AA = Asp, Glu, Tyr and Cys. (C) 2002 Elsevier Science B.V. All rights reserved.

  DOI：

  10.1016/s0020-1693(02)00748-x
• 作为产物：
  描述：

  (2S)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxo-4-[tris[(2-methylpropan-2-yl)oxy]silyloxy]butanoic acid 、 DL-苯基丙氨酸甲酯盐酸盐 生成 3-氨基-4-[(1-苄基-2-甲氧基-2-氧代乙基)氨基]-4-氧代丁酸
  参考文献：
  名称：

  GRUSZECKI, WOJCIECH;GRUSZECKA, MARIA;BRADACZEK, HANS

  摘要：

  DOI：

文献信息

• [EN] IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS IMIDAZOLE UTILES COMME INHIBITEURS DE LA FAAH
  申请人：MERCK & CO INC

  公开号：WO2009152025A1

  公开（公告）日：2009-12-17

  The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

  本发明涉及某些咪唑衍生物，其可用作脂肪酰胺水解酶（FAAH）的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方，以及这些化合物及其配方在治疗某些疾病中的使用，包括骨关节炎、类风湿性关节炎、糖尿病性神经病、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
• [EN] PYRAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS DE PYRAZOLE UTILES COMME INHIBITEURS DE FAAH
  申请人：MERCK & CO INC

  公开号：WO2009151991A1

  公开（公告）日：2009-12-17

  The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzheimer disease, and Parkinson's disease

  本发明涉及某些咪唑衍生物，其可用作脂肪酰胺水解酶（FAAH）的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方，以及这些化合物及其配方在治疗某些疾病中的使用，包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
• [EN] COMPOUNDS FOR USE AS PROTON CHANNELS AND METHODS THEREOF<br/>[FR] COMPOSÉS DESTINÉS À ÊTRE UTILISÉS EN TANT QUE CANAUX DE PROTONS ET PROCÉDÉS ASSOCIÉS
  申请人：AGENCY SCIENCE TECH & RES

  公开号：WO2020159441A1

  公开（公告）日：2020-08-06

  The present disclosure relates generally to compounds or a salt, solvate, stereoisomer and prodrug thereof for forming synthetic membrane channels. The present disclosure also relates to methods of synthesizing the compounds, methods of forming the synthetic membrane channels and methods of use thereof. In particular, the synthetic membrane channels are synthetic proton channels in a lipid membrane.

  本公开涉及一般用于形成合成膜通道的化合物或其盐、溶剂化合物、立体异构体和前药。本公开还涉及合成该化合物的方法、形成合成膜通道的方法以及使用方法。具体而言，合成膜通道是位于脂质膜中的合成质子通道。
• [EN] BICYCLIC ARYL SPHINGOSINE 1-PHOSPHATE ANALOGS<br/>[FR] ANALOGUES D’ARYLSPHINGOSINE-1-PHOSPHATE BICYCLIQUES
  申请人：BIOGEN IDEC INC

  公开号：WO2011017561A1

  公开（公告）日：2011-02-10

  Compounds that have agonist activity at one or more of the SlP receptors are provided. The compounds are sphingosine analogs that, after phosphorylation, can behave as agonists at SlP receptors.

  提供具有在一个或多个SlP受体上拮抗活性的化合物。这些化合物是鞘氨醇类似物，在磷酸化后可以在SlP受体上表现为拮抗剂。
• [EN] OXAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS D'OXAZOLE UTILES COMME INHIBITEURS DE FAAH
  申请人：MERCK & CO INC

  公开号：WO2010017079A1

  公开（公告）日：2010-02-11

  The present invention is directed to certain oxazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

  本发明涉及某些噁唑衍生物，其可用作脂肪酸酰胺水解酶（FAAH）的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方，以及这些化合物及其配方在治疗某些疾病中的使用，包括骨关节炎、类风湿性关节炎、糖尿病神经病变、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。